+ Part IX · Regulation
Quality and regulation, as of November 2026.
On 25 May 2026 FDA entered the sixth edition of ISO 10993-1 in its database of recognized standards, with one clause and one phrase left out. The Federal Register list that makes the change applicable followed just under three months later, on 24 August 2026. The earlier chapters teach why each rule exists: why molecules leave a material, how a dose is weighed against a tolerable intake, and why the evaluation became an estimate of risk. This part maps three jurisdictions onto that reasoning, as of November 2026: the United States (Chapter 26), the European Union (Chapter 27) and India (Chapter 28). Each status is a dated fact, and a draft is named as a draft. The part serves two decisions in a file: which edition of each standard it declares, and which route to the market it takes in each jurisdiction.
The risk assessment first, the recognized edition named.
+ The questionWhat does FDA expect of a biological evaluation, as of November 2026?
A court order sets the terms of a return
On 9 April 2024 a federal court in Pennsylvania entered a consent decree that set out what Philips Respironics must do before it could again make and sell new sleep machines in the US. The decree settled a complaint that the Justice Department had filed for FDA five days earlier (Chapter 20). The department called the complaint's claims "allegations only", with "no determination of liability".
The decree's central term leaves the decision to restart with FDA. In FDA's summary, the decree restricts "the production and sale of new continuous positive airway pressure (CPAP) machines", with limited exceptions, until the firm meets the decree's requirements. The restriction applies at the five facilities the decree lists, four in Pennsylvania and one in California. Under the decree, an independent quality-system expert inspects the facilities, following a work plan that FDA approves in writing. Production and sale may resume only after FDA states in writing that the facilities "appear to be in compliance", and the decree rules out any other signal: "In no circumstance shall FDA's silence be construed as a substitute for written notification."
Two further terms concern the patients and the replacement foam. FDA agreed a recall remediation plan on 28 March 2024, and under it patients receive a new or remediated device or, for some models, a refund "factoring in depreciation of the device". The decree names the replacement the New Foam: the "sound abatement foam used to replace or used in lieu of the PE-PUR". The PE-PUR is the recalled polyester polyurethane foam. FDA's summary calls the New Foam silicone-based. Within ten days of the decree's entry, Philips was to retain an independent testing expert to review the New Foam's testing, a review that is to "enable a determination that the New Foam does not degrade during the labeled service life of the Device".
The decree's testing plan follows the order of the gas-pathway evaluation in Chapters 19 and 22: the breathed gas first, and the materials only where the gas results leave a risk open. The expert's review covers three assessments of the gas, each under ISO 18562. The first is a "biocompatibility evaluation and risk management review" under part 1. The second covers the volatile organic compounds that the foam emits, with "analytical and toxicological risk assessments" under part 3. The third is a set of particle tests of the replacement and reworked devices, under parts 1 and 2. Only where those three assessments leave the risk "not sufficiently mitigated" does the plan turn to ISO 10993, for the New Foam's chemical characterization and biological evaluation.
The decree was the last step in the case, after the recall of 2021, FDA's order of March 2022 and a second order that FDA only proposed (Chapter 20). Philips Respironics says in its recall FAQ of 3 November 2026 that it "will resume sales of new CPAP or BiPAP sleep therapy devices" only when the decree's requirements are met, and that outside the US it continues to provide new devices. On that wording, US sales of new machines had not resumed by that date.
FDA asks for the risk assessment first
FDA sets out what it expects of a biological evaluation in its guidance Use of International Standard ISO 10993-1. FDA issued the guidance on 8 September 2023 to replace a version of 2020 (Chapter 21). The guidance says what FDA recommends that a submission contain. Its first recommendation fixes an order: the risk assessment goes "at the beginning of the biocompatibility section", before any test report. That assessment names the knowledge gaps that remain and the plan to address them, so each test that follows answers a question the assessment has already asked (Chapter 22).
Two further recommendations decide what is tested and what the file holds. FDA wants the information "for the device in its final finished form", after the processing and sterilization of Chapters 6 and 7, which change the materials. It also asks that "complete test reports be provided for all tests performed". The guidance was written for the 2018 edition of ISO 10993-1, and FDA has not changed it for the 2025 edition (Chapter 21).
FDA recognizes a standard one edition at a time
FDA recognizes a consensus standard by entering one edition of it, in full or in part, in its database of recognized standards. The record for each edition gives the date of entry. A premarket submission can then make a declaration of conformity to the recognized edition, in which the submitter certifies that the device conforms to all the requirements of the recognized standard, with no deviation from them. That is how FDA's 2018 guidance on consensus standards defines the declaration. FDA also publishes each change to the database in the Federal Register, as a list of modifications. A recognition therefore has two dates: its entry in the database and the publication of the list.
For ISO 10993-1 those dates are 25 May 2026, when FDA entered the 2025 edition, and 24 August 2026, when FDA published the list that marked the recognition of the 2018 edition "Withdrawn and replaced with newer version." FDA recognizes the 2025 edition in part, and Chapter 21 explains the clause and the phrase that FDA leaves out. The 2018 edition stays usable for a time: FDA "will accept declarations of conformity, in support of premarket submissions" to the 2018 edition "until July 1, 2029", the record of the 2025 edition states.
- The end date. FDA accepts declarations to the 2018 edition until 1 July 2029. FDA's town hall slides of 9 September 2026 call the window a "Transition period: 3 years" and name no start date.
- From this book's date. From 1 November 2026 to 1 July 2029 is 2 years and 8 months, or 32 months.
- The result. A maker that declares the 2018 edition has about 32 months from November 2026 to submit the file. On this book's reading the date of submission is the one that counts, since FDA accepts the declarations "in support of premarket submissions", so a maker that will submit after 1 July 2029 writes the file to the 2025 edition from its first plan.
- Assumptions. FDA "may update" a standard's record, as its town hall slides state, so the end date is the record's as of November 2026.
Each part of ISO 10993 has its own record, so the edition a file can declare differs from part to part. Part 3 holds the genotoxicity tests of Chapter 18, and in November 2026 FDA still recognized its 2014 edition, not its 2026 edition. Chapters 7 and 9 report the same for parts 7 and 6, whose 2026 editions FDA had not recognized either.
The device's class sets the route
The device's class decides which submission the evaluation goes into. FDA sorts devices into three classes, which its regulation calls "categories of regulatory control". FDA's own page ranks them from the lowest risk in class I to the greatest in class III. A class I or II device that is not exempt needs a 510(k), which FDA clears on substantial equivalence to a legally marketed device. A novel device of "low to moderate risk" can be classified through a De Novo request, which FDA grants. Class III is the class for which premarket approval is or will be required. A device of a type for which FDA requires premarket approval needs a premarket approval application, which FDA approves.
FDA's 2023 guidance applies to all three routes, and also to applications for humanitarian device exemptions and investigational device exemptions. In each of these submissions the biocompatibility section therefore opens with the risk assessment. The chemical analysis inside that section has a guidance of its own, Chemical Analysis for Biocompatibility Assessment of Medical Devices. FDA issued it in September 2024 as a draft, not for implementation, and in November 2026 it is still a draft. The draft recommends how to extract a device, analyze the extract and set the threshold for reporting compounds, the steps that Chapters 12 to 17 follow.
Outside the biological evaluation, one US requirement names a kind of material: the color additive. A device whose color additive directly contacts the body for a significant period needs a regulation "in effect listing the color additive for which it is intended to be used". FDA states the rule on its 2022 page on color additives in devices and has not defined the period. Because the rule names both the additive and its use, this book reads it as requiring a new colorant to be listed for its use, and a change of colorant to be checked against the listing as well as under change control (Chapter 23).
The quality system catches later changes
A file describes the device on the day it is sent, while its materials and suppliers can change afterward. The controls that catch such changes sit in the Quality Management System Regulation, the QMSR. The QMSR is the amended rule for device makers' quality systems, and it became effective on 2 February 2026. Design controls were required before it, under the Quality System Regulation. The QMSR incorporates by reference ISO 13485:2016, the quality-system standard, and, for class II and class III devices and some class I devices, takes its design and development requirements from the standard's clause 7.3. ISO 13485:2016 "now specifically requires risk management", FDA's page on the rule notes.
The QMSR does not incorporate ISO 14971 or the other standards that ISO 13485 cites, although FDA's final rule says that such standards "may be helpful in understanding application of ISO 13485". On this book's reading, a US maker therefore owes the risk management of Chapter 22 to ISO 13485's own risk requirements, which the QMSR incorporates, and not to ISO 14971 itself. On the same reading, the maker follows the guidance on ISO 10993-1 as FDA's recommendations for the biological evaluation. The supplier and change controls that keep the evaluation current are ISO 13485's, and Chapter 23 sets them out.
The running device's US file
This book's US file for the running device is an illustration, not any maker's file. Machines of its kind belong to a device type, the non-continuous ventilator, that FDA's classification database lists in class II. The database lists a respiratory gas humidifier in class II as well. FDA has cleared such machines through 510(k)s, as makers' summaries show, and the book files the running device through a 510(k) too. The evaluation plan of Chapter 22 assesses the gas pathway under ISO 18562, the polyether polyurethane foam and the water chamber included (Chapter 19). The plan submits the silicone cushion to the extraction and analysis of Chapters 12 to 17 and to the local lymph node assay for sensitization (Chapter 18).
The plan names the 2025 edition of ISO 10993-1, as Chapter 22 built it, so the end of the transition for the 2018 edition does not affect it. For the US file the plan estimates the biological risk under ISO 14971:2019, in place of the clause that FDA left out (Chapter 21). In July 2026 FDA cleared one maker's breathing machine with an integrated humidifier, and the maker's own 510(k) summary of that machine lists standards, not results: it names seven parts of ISO 10993 and all four of ISO 18562, and it states no values.
Name FDA's 2023 guidance and the edition of ISO 10993-1 the file declares, and submit a file on the 2018 edition by 1 July 2029. Open the biocompatibility section with the risk assessment and the plan, attach complete reports of every test, and cite the chemical analysis guidance as a draft. For a colored part that contacts the body for a significant period, check that its color additive is listed for that use. Keep supplier and change records under ISO 13485 (Chapter 23).
- With limited exceptions, the consent decree of 9 April 2024 restricts new CPAP production and sale at the covered facilities until FDA gives written notice. Its plan for the New Foam tests the breathed gas under ISO 18562 before ISO 10993.
- FDA's guidance on ISO 10993-1 recommends the risk assessment first in the biocompatibility section and complete reports of every test. FDA issued it on 8 September 2023 and wrote it for the 2018 edition.
- FDA entered the 2025 edition in its database on 25 May 2026, recognizing it in part, and published the change on 24 August 2026. It accepts declarations to the 2018 edition until 1 July 2029.
- FDA's 2023 guidance applies alike to 510(k)s, De Novo requests and premarket approval applications. The QMSR became effective on 2 February 2026 and incorporates ISO 13485 but not ISO 14971.
Let's Talk